



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 31 August 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

Important notices

- OMB Approval for Form Changes Underway - Continue to Use Current Forms Until Further Notice ([NOT-OD-15-146](#))
- Notice of Correction in PA-15-312 "Research to Advance Vaccine Safety (R01) ([NOT-AI-15-052](#)) (R21)" ([NOT-AI-15-053](#))
- NINDS Announces Interest in Large Randomized Emergency Care Clinical Trials ([NOT-NS-15-039](#))
- Notice of Participation of Additional NIH Components in PAR-15-292 "Emerging Global Leader Award (K43)" ([NOT-TW-15-004](#))

1. Title: Urinary Stone Disease Research Network: Clinical Centers (USDRN-CCs) Collaborative

Letter of Intent due date: October 18, 2015

Hyperlink: ([RFA-DK-15-004](#)) Type: UO1

Application Due Date: Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Internal Submission will be 2 days before the application due date above.

Purpose: November 18, 2015, by 5:00 PM local time of applicant organization. This FOA invites collaborative cooperative agreement applications to establish a multi-center, multi-disciplinary group of investigators to be known as the Urinary Stone Disease Research Network (USDRN). The USDRN will a) design and conduct a randomized clinical trial to investigate the impact of increased fluid intake and increased urine output on the rate of recurrence of urinary stones in adults and children, b) conduct clinical research to understand and mitigate ureteral stent-related pain and symptoms, and c) provide data and collect biological samples from the studies to create a resource for future researchers. RFA-DK-15-005 will support the USDRN Scientific Data Research Center.

Budget: Application budgets are limited to \$450,000 direct costs for each Clinical Center. Maximum period 5 years.

2. Title: Urinary Stone Disease Research Network: Scientific Data Research Center (USDRN-SDRC) Collaborative

Letter of Intent due date: October 18, 2015

Hyperlink: ([RFA-DK-15-005](#)) Type: UO1

Application Due Date: November 18, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This FOA invites cooperative agreement applications to establish a multi-center, multi-disciplinary group of investigators to be known as the Urinary Stone Disease Research Network (USDRN). This FOA solicits applications for the Scientific Data Research Center (SDRC) and runs in parallel with a separate FOA that invites applications for the Clinical Centers (CCs) (RFA-DK-15-004). The USDRN will a) design and conduct a randomized clinical trial (RCT) to investigate the impact of increased fluid intake and increased urine output on the rate of recurrence of urinary stones in adults and children, b) conduct clinical research to understand and mitigate ureteral stent-related pain and symptoms, and c) provide data and collect biological samples from the studies to create a resource for future researchers. RFA-DK-15-004 will support USDRN Clinical Centers.

Budget: Application budgets are limited to \$700,000 direct costs for the Scientific Data Research Center. The maximum project period is 5 years.

3. Title: BRAIN Initiative: Technology Sharing and Propagation

Letter of Intent due date: December 6, 2015

Hyperlink: ([RFA-MH-16-725](#)) Type: RO3

Application Due Date: January 6, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Funding Opportunity Announcement (FOA) is to encourage the transfer of new technologies and new data analysis techniques into a research laboratory. One of the key goals of the BRAIN Initiative is to develop new technologies to improve our understanding of the brain. In order for those technologies to be useful, they need to be broadly disseminated beyond the laboratory or company where they originated. This FOA promotes this goal by providing funds to enable the incorporation of new technologies or data analysis techniques into research programs that further the aims of the BRAIN initiative.

Budget: Total direct costs may not exceed \$100K, with \$50K in direct costs reserved for the purchase or lease of equipment, or purchase or licensing of software. The budget needs to reflect the actual needs of the proposed project. The maximum project period is one year.

4. Title: Abuse Liability Associated with Reduced Nicotine Content Tobacco Products

Letter of Intent due date: Although Letters of Intent are typically requested one month before the due date, letters of intent for this FOA are requested for October 30, 2015

Hyperlink: [\(RFA-OD-15-006\)](#)

Type: RO1

Application Due Date: December 11, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to generate data to inform the FDA on ways to reduce the addictiveness and resulting public health toll from tobacco product use in the United States. Nicotine is the primary constituent responsible for the addictiveness of cigarettes, resulting in smokers' inability to quit and continued use. Research addressing nicotine and combusted tobacco product use behaviors (e.g., reinforcing effects, compensation, and amount used) and the dose-effects of nicotine will inform FDA regarding its tobacco regulatory authorities. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by the National Institutes of Health (NIH) using designated funds from the FDA CTP for tobacco regulatory science.

Budget: Application budgets are not to exceed \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa Coetsee** • Tel: 9838 • Email: cdevries@sun.ac.za